ArticleJournal of Korean medical science2025
Sexual Risk Compensation and Retention in PrEP Care in Korea: An HIV PrEP Demonstration Study.
Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Comparative Analysis of Pre-Exposure Prophylaxis Awareness, Acceptance, and Barriers Among Populations of Men Who Have Sex with Men in Global Settings: An Integrative Literature Review.Nursing reports (Pavia, Italy) · 2026Review
- Feasibility and Preferences to Adopt mHealth-Based Interventions for HIV Prevention Among High-Risk Groups: Cross-Sectional Study.JMIR human factors · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) is effective in preventing human immunodeficiency virus (HIV), however, its feasibility has not been evaluated in the Republic of Korea (Korea). Therefore, this study aimed to assess the feasibility of PrEP in men who have sex with men (MSM) in Korea. This is the first demonstration study in Korea, in which PrEP medication, laboratory tests, and clinic visit fees were provided without charge to participants.
methodsHIV-negative MSM were prescribed daily TDF-FTC and followed up at an outpatient clinic. At each visit, adverse reactions, adherence, and sexual behavior were assessed using a questionnaire, and residual pills and blood and urine samples were collected. Tenofovir diphosphate (TFV) concentrations were measured in plasma and urine.
resultsOne hundred participants were enrolled and followed up for a median of 392 days. The retention-in-care was 77%. The incidence of HIV and other sexually transmitted infections (STIs) was 0.98 and 13.67 per 100 person-years, respectively. No serious adverse events were detected. Among the participants, 55.3% (47/85) and 41.7% (25/60) had plasma TFV concentrations > 40 ng/mL at weeks 28 and 52, respectively. Residual pill counts and self-reported adherence were not correlated with plasma TFV levels. Participants with positive STI test results were significantly more likely to have plasma TFV concentrations > 40 ng/mL (adjusted odds ratio, 3.67;
conclusionDaily oral PrEP was safe and effective in MSM and not associated with increased sexual risk behavior. To our knowledge, this is the first analysis of risk compensation among PrEP users in East Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.